scholarly journals MRJP1-containing glycoproteins isolated from honey, a novel antibacterial drug candidate with broad spectrum activity against multi-drug resistant clinical isolates

2015 ◽  
Vol 6 ◽  
Author(s):  
Katrina Brudzynski ◽  
Calvin Sjaarda ◽  
Robert Lannigan
Keyword(s):  
Broad Spectrum ◽  
Clinical Isolates ◽  
Drug Candidate ◽  
Antibacterial Drug ◽  
Drug Resistant ◽  
Spectrum Activity ◽  
Broad Spectrum Activity

scholarly journals Five-Year Longitudinal Assessment (2008 to 2012) of E-101 Solution Activity against Clinical Target and Antimicrobial-Resistant Pathogens

2014 ◽  
Vol 58 (8) ◽  
pp. 4911-4914 ◽  
Author(s):  
Gerald A. Denys ◽  
Chris M. Pillar ◽  
Daniel F. Sahm ◽  
Peter O'Hanley ◽  
Jackson T. Stephens
Keyword(s):  
Broad Spectrum ◽  
Susceptibility Testing ◽  
Bacterial Species ◽  
Clinical Isolates ◽  
Longitudinal Assessment ◽  
Gram Negative ◽  
Spectrum Activity ◽  
Eskape Pathogens ◽  
Negative Target ◽  
Broad Spectrum Activity

ABSTRACTThis study summarizes the topical E-101 solution susceptibility testing results for 760 Gram-positive and Gram-negative target pathogens collected from 75 U.S. sites between 2008 and 2012 and 103 ESKAPE pathogens. E-101 solution maintained potent activity against all bacterial species studied for each year tested, with MICs ranging from <0.008 to 0.25 μg porcine myeloperoxidase (pMPO)/ml. These results confirm that E-101 solution retains its potent broad-spectrum activity against U.S. clinical isolates and organisms with challenging resistance phenotypes.

scholarly journals In VitroAntimicrobial Activity of Razupenem (SMP-601, PTZ601) against Anaerobic Bacteria

2011 ◽  
Vol 55 (5) ◽  
pp. 2398-2402 ◽  
Author(s):  
Chau Minh Tran ◽  
Kaori Tanaka ◽  
Yuka Yamagishi ◽  
Takatsugu Goto ◽  
Hiroshige Mikamo ◽  
...  
Keyword(s):  
Broad Spectrum ◽  
Anaerobic Bacteria ◽  
Clinical Isolates ◽  
Strong Activity ◽  
Content Type ◽  
Spectrum Activity ◽  
Reference Strains ◽  
Gram Positive Cocci ◽  
Broad Spectrum Activity

ABSTRACTWe evaluated thein vitroantianaerobic activity of razupenem (SMP-601, PTZ601), a new parenterally administered carbapenem, against 70 reference strains and 323 clinical isolates. Razupenem exhibited broad-spectrum activity against anaerobes, inhibiting most of the reference strains when used at a concentration of ≤1 μg/ml. Furthermore, it exhibited strong activity, comparable to those of other carbapenems (meropenem and doripenem), against clinically isolated non-fragilis Bacteroidesspp. (MIC90s of 2 μg/ml), with MIC90values of 0.06, 0.03, and 0.5 μg/ml againstPrevotellaspp.,Porphyromonasspp., andFusobacteriumspp., respectively. Clinical isolates of anaerobic Gram-positive cocci,Eggerthellaspp., andClostridiumspp. were highly susceptible to razupenem (MIC90s, 0.03 to 1 μg/ml).

scholarly journals 1370. Cefepime/VNRX-5133 Broad-Spectrum Activity Is Maintained Against Emerging KPC- and PDC-Variants in Multidrug-Resistant K. pneumoniae and P. aeruginosa

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S419-S420 ◽  
Author(s):  
Denis Daigle ◽  
Jodie Hamrick ◽  
Cassandra Chatwin ◽  
Natalia Kurepina ◽  
Barry N Kreiswirth ◽  
...  
Keyword(s):  
Broad Spectrum ◽  
Susceptibility Testing ◽  
Multidrug Resistant ◽  
Clinical Development ◽  
Clinical Isolates ◽  
Research Support ◽  
Class A ◽  
Highly Active ◽  
Spectrum Activity ◽  
Broad Spectrum Activity

Abstract Background VNRX-5133 is a cyclic boronate β-lactamase inhibitor (BLI) currently in clinical development with cefepime to treat multidrug-resistant (MDR) infections caused by ESBL- and carbapenemase-producing Enterobacteriaceae (ENT) and P. aeruginosa (PSA). VNRX-5133 has direct inhibitory activity against serine-active site β-lactamases (Ser-BL) and emerging VIM/NDM metallo-β-lactamases (MBL). We show herein that cefepime/VNRX-5133 is highly active against MDR-K. pneumoniae and P. aeruginosa clinical isolates producing BL-variants evolved during therapy that compromise activity of ceftazidime/avibactam and ceftolozane/tazobactam. Methods Susceptibility testing was performed according to CLSI methods with cefepime, ceftolozane, and ceftazidime alone or in combination with VNRX-5133, avibactam, or tazobactam, respectively, fixed at 4 mg/L. Five clinical isolates of K. pneumoniae producing KPC variants impacting ceftazidime/avibactam and five clinical isolates of P. aeruginosa producing Pseudomonas-derived cephalosporinase variants impacting ceftolozane/tazobactam activity were collected in 2016 and 2017, respectively, from United States and Spanish hospitals. All other clinical isolates of Enterobacteriaceae and P. aeruginosa (n = 40) were collected in 2016. Results Cefepime/VNRX-5133 was highly active against five ceftazidime/avibactam-resistant K. pneumoniae clinical isolates producing KPC variants with MIC ranging from 0.5 to 4 mg/L relative to ceftazidime/avibactam MIC range of 16 to &gt;128 mg/L. Cefepime/VNRX-5133 was also active against all five clinical isolates of ceftolozane/tazobactam-resistant P. aeruginosa, where 4/5 isolates had MIC of 4–8 mg/L relative to ceftolozane/tazobactam MIC range of 32–128 mg/L. The elevated cefepime/VNRX-5133 MIC (16 mg/L) in the remaining P. aeruginosa isolate was not due to the PDC-221 variant, as an engineered strain of P. aeruginosa producing this enzyme had a cefepime/VNRX-5133 MIC of 1 mg/L. Conclusion VNRX-5133 is a potent BLI possessing a unique broad spectrum of activity, including Class A, C, and D Ser-BLs, clinically evolving variants of Ser-BLs (e.g., KPC, PDC) and emerging VIM/NDM-type MBLs. Cefepime/VNRX-5133 is highly active against emerging multidrug-resistant Enterobacteriaceae and P. aeruginosa. Disclosures D. Daigle, VenatoRx Pharmaceuticals Inc.: Employee and Shareholder, Salary. J. Hamrick, VenatoRx Pharmaceuticals Inc.: Employee, Salary. C. Chatwin, VenatoRx Pharmaceuticals Inc.: Employee, Salary. N. Kurepina, VenatoRx Pharmaceuticals Inc.: Research Contractor, Research support. B. N. Kreiswirth, VenatoRx Pharmaceuticals Inc.: Research Contractor, Research support. R. K. Shields, VenatoRx Pharmaceuticals Inc.: Research Contractor, Research support. A. Oliver, VenatoRx Pharmaceuticals Inc.: Research Contractor, Research support. C. J. Clancy, VenatoRx Pharmaceuticals Inc.: Research Contractor, Research support. M. H. Nguyen, VenatoRx Pharmaceuticals Inc.: Research Contractor, Research support. D. Pevear, VenatoRx Pharmaceuticals Inc.: Employee, Salary. L. Xerri, VenatoRx Pharmaceuticals Inc.: Employee and Shareholder, Salary.

Efficacy of some medicated soaps and hand washes available in market

2021 ◽  
Vol 3 (1) ◽  
pp. 047-055
Author(s):  
Pimpliskar Mukesh ◽  
SoumyaGounder ◽  
Rahul Jadhav
Keyword(s):  
Broad Spectrum ◽  
Life Forms ◽  
Small Scale ◽  
Gram Positive ◽  
Consistent Finding ◽  
Gram Negative ◽  
Cross Transmission ◽  
Spectrum Activity ◽  
Significant Measure ◽  
Broad Spectrum Activity

Background: Handwashing is underlined as the absolute most significant measure to forestall cross-transmission of small-scale life forms and consequently to forestall nosocomial contaminations. Be that as it may, under routine emergency clinic practice consistent with this measure is still unsatisfactorily low, under half in many investigations distributed in the previous 20 years. This consistent finding is stressing because ongoing investigations have demonstrated that this degree of consistency won't decrease the danger of transmission of multi- medicate safe microscopic organisms in the emergency clinics. Results: In the present investigation effect of marketed hand washed namely Lifebuoy, Dettol and Savlon were tested on bacteria E. coli, S.aureus, S.pyogen, Klebshiella and, fungi Candida albicans. All the handwash at concentrated level found to be effective but only Dettol hand wash could give inhibitory action at 25ug/ml against Klebshiella while others at50ug/ml. Conclusions: Soapex and Dettol soap had broad spectrum activity as it inhibited the growth of Gram positive (Streptococcus pyogen) and Gram-negative (Escherichia coli). Liquid handwash such as Lifebuoy,Dettol and Savlon showed broad spectrum activity on both Gram-positive and Gram negative test microorganisms.

scholarly journals Correction: Novel broad-spectrum activity-based probes to profile malarial cysteine proteases

PLoS ONE ◽  
2020 ◽  
Vol 15 (3) ◽  
pp. e0231231
Author(s):  
Michele S. Y. Tan ◽  
Dara Davison ◽  
Mateo I. Sanchez ◽  
Bethany M. Anderson ◽  
Stephen Howell ◽  
...  
Keyword(s):  
Broad Spectrum ◽  
Cysteine Proteases ◽  
Spectrum Activity ◽  
Broad Spectrum Activity

scholarly journals Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 2

2020 ◽  
Vol 11 (12) ◽  
pp. 1379-1385
Author(s):  
R. Kirk ◽  
A. Ratcliffe ◽  
G. Noonan ◽  
M. Uosis-Martin ◽  
D. Lyth ◽  
...  
Keyword(s):  
Broad Spectrum ◽  
Bacterial Infections ◽  
Rational Design ◽  
Topoisomerase Ii ◽  
Topoisomerase Inhibitors ◽  
Design Synthesis ◽  
Pharmacokinetic Properties ◽  
Spectrum Activity ◽  
Broad Spectrum Activity

We disclose the discovery of REDX07965, a novel tricyclic topoisomerase inhibitor (NTTI) which has broad spectrum activity, favourable in vitro pharmacokinetic properties and selectivity versus human topoisomerase II.

Alkoxyphenylthiazoles with broad-spectrum activity against multidrug-resistant gram-positive bacterial pathogens

2018 ◽  
Vol 152 ◽  
pp. 318-328 ◽  
Author(s):  
Moustafa ElAwamy ◽  
Haroon Mohammad ◽  
Abdelrahman Hussien ◽  
Nader S. Abutaleb ◽  
Mohamed Hagras ◽  
...  
Keyword(s):  
Broad Spectrum ◽  
Bacterial Pathogens ◽  
Multidrug Resistant ◽  
Gram Positive ◽  
Spectrum Activity ◽  
Broad Spectrum Activity

scholarly journals Identification of Broad-Spectrum Antiviral Compounds by Targeting Viral Entry

Viruses ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 176 ◽  
Author(s):  
Michela Mazzon ◽  
Ana Ortega-Prieto ◽  
Douglas Imrie ◽  
Christin Luft ◽  
Lena Hess ◽  
...  
Keyword(s):  
Viral Entry ◽  
Broad Spectrum ◽  
Well Being ◽  
Screening Strategy ◽  
Life Cycles ◽  
Antiviral Compounds ◽  
Spectrum Activity ◽  
Cellular Pathways ◽  
Broad Spectrum Activity ◽  
Economic Well Being

Viruses are a major threat to human health and economic well-being. In recent years Ebola, Zika, influenza, and chikungunya virus epidemics have raised awareness that infections can spread rapidly before vaccines or specific antagonists can be made available. Broad-spectrum antivirals are drugs with the potential to inhibit infection by viruses from different groups or families, which may be deployed during outbreaks when specific diagnostics, vaccines or directly acting antivirals are not available. While pathogen-directed approaches are generally effective against a few closely related viruses, targeting cellular pathways used by multiple viral agents can have broad-spectrum efficacy. Virus entry, particularly clathrin-mediated endocytosis, constitutes an attractive target as it is used by many viruses. Using a phenotypic screening strategy where the inhibitory activity of small molecules was sequentially tested against different viruses, we identified 12 compounds with broad-spectrum activity, and found a subset blocking viral internalisation and/or fusion. Importantly, we show that compounds identified with this approach can reduce viral replication in a mouse model of Zika infection. This work provides proof of concept that it is possible to identify broad-spectrum inhibitors by iterative phenotypic screenings, and that inhibition of host-pathways critical for viral life cycles can be an effective antiviral strategy.

Sign in / Sign up

Export Citation Format

Share Document